LYZZ Capital is a leading global healthcare-dedicated VC/PE firm. We currently are actively investing out of USD and RMB funds totaling over USD$460 million. The LYZZ team is composed of highly experienced investment and operating professionals from leading pharmaceutical/biotech companies and Wall Street firms with strong scientific and medical professionals background. We’ve worked together for over a decade and have cultivated a cordial, flat and team-oriented working environment. Our team’s biotech investment experience extends back over 15 years, with more 10 years of presence in China alone. We invest in talents, assets and technologies globally, with an emphasis on unmet medical needs and large market potential in China.
Looking for a particular LYZZ CAPITAL employee's phone or email?
The LYZZ CAPITAL annual revenue was $6.5 million in 2026.
Kevin Li is the Co-Founder and Managing Partner of LYZZ CAPITAL.
5 people are employed at LYZZ CAPITAL.
LYZZ CAPITAL is based in Shanghai, Shanghai.
The NAICS codes for LYZZ CAPITAL are [523, 52, 5239].
The SIC codes for LYZZ CAPITAL are [679, 67].